Affiliation: Stanford University
- Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivoXinrui Yan
Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
Mol Cancer 7:19. 2008..In this study, we validated the over-expression of CDC25B in HCC, and further investigated its potential as a therapeutic target for the management of HCC...
- Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenograftsWei Wei
Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, CA
Oncotarget 5:5819-31. 2014..We demonstrated that HSP90/CDC37 antagonists are potentially broad spectrum agents that might be beneficial for treating the heterogeneous subtypes of HCC, either as monotherapy, or in combination with other chemotherapeutic agents...
- Development and validation of non-integrative, self-limited, and replicating minicircles for safe reporter gene imaging of cell-based therapiesJohn A Ronald
Molecular Imaging Program at Stanford, Stanford University, Stanford, California, United States of America Department of Radiology, Stanford University, Stanford, California, United States of America
PLoS ONE 8:e73138. 2013..This will lead to safe tools to assess treatment response at earlier time points and improve the precision of cell-based therapies...
- N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cellsXinrui Yan
Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305 5655, USA
Cancer Lett 262:133-42. 2008..These results are consistent with our earlier clinical observations that NDRG1 is associated with more aggressive tumor behavior, and suggest that NDRG1 may be a potential therapeutic target for HCC...